Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) FCF Margin (2016 - 2025)

Adma Biologics (ADMA) has disclosed FCF Margin for 13 consecutive years, with 24.83% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 1554.0% year-over-year to 24.83%, compared with a TTM value of 5.45% through Dec 2025, down 2045.0%, and an annual FY2025 reading of 5.45%, down 2045.0% over the prior year.
  • FCF Margin was 24.83% for Q4 2025 at Adma Biologics, up from 0.8% in the prior quarter.
  • Across five years, FCF Margin topped out at 40.66% in Q2 2024 and bottomed at 223.07% in Q1 2021.
  • Average FCF Margin over 5 years is 37.85%, with a median of 16.38% recorded in 2023.
  • The sharpest move saw FCF Margin soared 18912bps in 2021, then plummeted -5768bps in 2022.
  • Year by year, FCF Margin stood at 67.53% in 2021, then plummeted by -85bps to 125.21% in 2022, then skyrocketed by 118bps to 22.19% in 2023, then surged by 82bps to 40.37% in 2024, then crashed by -38bps to 24.83% in 2025.
  • Business Quant data shows FCF Margin for ADMA at 24.83% in Q4 2025, 0.8% in Q3 2025, and 15.34% in Q2 2025.